Alzheon Announces Patent Allowance In Europe For ALZ-801 In Development For Alzheimer’s Disease
LEXINGTON, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that the European Patent Office has issued a notification of intent to grant a patent directed to the company’s lead product candidate ALZ-801. The allowed claims, when issued as patents in 2015, will extend Alzheon’s protection for the composition of matter of ALZ-801 and pharmaceutical compositions containing ALZ-801, as well as for methods of treating Alzheimer’s disease and other disorders using ALZ-801, into key pharmaceutical markets in Europe. The European allowance follows the issuance of patents in 2014 directed to ALZ-801 in the United States and Japan.
“We are pleased to obtain this patent allowance and expand our foundational patent protection for ALZ-801 into Europe”
ALZ-801 is a novel small molecule inhibitor of neurotoxicity and amyloid aggregation with potential to be a first-in-class therapy for a genetically defined population of patients with or at high risk for Alzheimer’s disease.
“We are pleased to obtain this patent allowance and expand our foundational patent protection for ALZ-801 into Europe,” said Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer of Alzheon. “With a strong intellectual property estate for ALZ-801 in the world’s largest pharmaceutical markets, we are well positioned to execute on our plans to advance this innovative product candidate into a potentially pivotal study in Alzheimer’s disease in late 2015, and to establish Alzheon as a leader in the development of new treatments for neurodegenerative diseases.”
About Alzheon
Alzheon, Inc., a clinical-stage biotechnology company focused on brain health, memory and aging, develops innovative treatments for Alzheimer’s disease and other neurological and psychiatric disorders. We pursue product candidates for which there is evidence of both target engagement and clinical safety and efficacy, and where new insights and development strategies can be applied. Our lead product candidate, ALZ-801, is a small molecule inhibitor of neurotoxicity and amyloid aggregation with potential to be a first-in-class therapy for a genetically defined population of patients with or at high risk for Alzheimer’s disease. Alzheon is located in Lexington, Massachusetts, USA. For more information, please visit www.alzheon.com.